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Pomegranate, Punica granatum L., is an authentic, generous fruit which is 
cultivated in many parts of the world for thousand years. The divine fruit was 
born from nature to provide humanity with its effluent benefits for life and health. 
Through the ages, Pomegranate occupied an eminent place in ayurvedic medi-
cine. It was prescribed for treatment of parasitic infection, diarrhea, and ulcers. 
Pomegranate wealth of prolific pharmacological activities makes it a rich culture 
for multiple studies in recent years. It will not be surprising if Pomegranate pro-
vides humans with a possible help in SARS-CoV-2 pandemic. The enemy that has 
raided the world since the end of 2019.
Keywords: ayurvedic medicine, phytochemicals, pomegranate, SARS-CoV-2
1. Introduction
Pomegranate (Punica granatum L.) is a common authentic fruit that is consumed 
for its health benefits in the globe. It contains many phytochemical constituents 
mainly Phenolic compounds which are responsible for most of its pharmacological 
properties [1, 2]. Several studies roamed in the Pomegranate field for its therapeutic 
benefits; anti- inflammatory, anti -oxidant, anti-cancer, anti- viral and immune 
modulation activities [3]. The fact that put pomegranate on the top of phytochemi-
cal agents with possible anti SARS-CoV-2 potential. Which has been attacking 
the earth for over a year. It is one of Coronaviruses, member of the subfamily 
Coronavirinae in the family Coronaviridae and the order Nidovirales [4].
2. Severe acute respiratory syndrome coronavirus-2, SARS-CoV-2
Corona viruses are wide group of viruses of humans as well as some animals. 
The clinical impact is ranged from mild to severe respiratory disease. In the last 
two decades, the world faced two aggressive coronaviruses: severe acute respira-
tory syndrome coronavirus (SARS-COV) in 2002 and Middle East respiratory 
syndrome coronavirus (MERS-COV) in 2012 [4]. At the end of 2019, SARS-CoV-2 
was reported in China, as an abnormal highly contagious viral pneumonia. Then 
shortly, the virus invaded the whole world [5, 6]. SARS-CoV-2 is an enveloped 
positive-sense single stranded RNA virus. It consists of four subunits, spike (S) 
glycoprotein, small envelope (E) glycoprotein, membrane (M) glycoprotein and 
nucleocapsid (N) protein [7]. Spike S protein with its two subunits, S1 and S2 is 
responsible for epithelial cell entry after its attachment to Angiotensin Converting 
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Enzyme 2, ACE2 receptors which is widely present in the respiratory tract and other 
parts of the body [8, 9]. While surface S1 subunit (specifically at receptor-binding 
domain, RDB region) attach to ACE2 receptor, transmembrane subunit (S2) starts 
membrane fusion between the virus and epithelial cell and begins endocytosis. 
This process is enabled by the two host cell enzymes; furin and transmembrane 
serine protease 2 (TMPRSS2) that cleaves S glycoprotein at S1/S2 [10, 11]. Then 
SARS-CoV-2 replicates and spreads down to the airways and occupies alveolar 
epithelial cells. Viral replication induces Intense immune response (Cytokine storm 
syndrome) with subsequent acute respiratory distress syndrome and respiratory 
failure, the main cause of death [12]. Treating SARS-CoV-2 infection is not easy, 
as we have not only to fight the virus and manage its respiratory sequalae, but we 
need to downregulate the hyper stimulated immune response as well. For this war, 
many agents have been recruited in different ways. Starting from Inhibition of virus 
entry as Umifenovir (Arbidol) that interferes with interaction between the viral S 
protein and ACE2 and block membrane fusion [13, 14]. Chloroquine and hydroxy-
chloroquine (two drugs of plant origin) are also thought to inhibit viral entry but 
with controversial results [15, 16]. Using soluble recombinant hACE2, specific 
monoclonal antibodies to occupy ACE2 receptors is another method to counter act 
viral entry [17, 18]. Inhibition of virus replication is another modality for treatment. 
There are numerous trials on remedesivir [15], favipiravir [19], ribavirin, lopinavir 
and ritonavir to inhibit viral replication [20]. Since SARS-CoV-2 over stimulates 
the immune response causing what is called, cytokine storm syndrome [21]. 
Immune modulation is a promising target for treatment. Dexamethasone decreased 
mortality in mechanically ventilated and oxygen receiving patients [22]. Plasma 
from recovered patients, convalescent plasma-derived hyperimmune globulin 
and monoclonal antibodies targeting SARS-CoV-2 were also tried in many trials 
[23–26]. Interleukin-6 (IL-6) has an important role in the inflammatory response. 
Tocilizumab, interleukin-6 (IL-6) receptor-specific antibody downregulated the 
immune response in small trials [27, 28]. Moreover, inhibition of pro inflammatory 
Complement 5 by Eculizumab, a specific monoclonal antibody, helped to decrease 
pulmonary oedema in severe COVID-19 patients [29]. Interferon plays a role in 
reducing of viral replication, type I interferons provide a treatment options in 
COVID-19 infection [30, 31]. Protein kinases inhibitors as Baricitinib, a reversible 
Janus-associated kinase (JAK)-inhibitor can help in SARS-CoV-2 treatment through 
its anti-inflammatory, anti-viral and antifibrotic properties [32]. Baricitinib attenu-
ated cytokine signaling in COVID-19 immune response. It also interfered with viral 
cell entry [33]. In another study, it improved with corticosteroids the respiration 
in SARS-CoV-2 pneumonia [34]. In addition, the Abl tyrosine kinase inhibitor 
(ATKI), imatinib was found to block viral fusion through attachment to receptor-
binding domain (RBD) of SARS-CoV-2 spike protein [35]. In spite of all the 
previous treatment modalities, there is no proven curative agent for SARS-CoV-2 
infection [36]. Which necessitates a continuous and hard search for new therapeutic 
agents including natural agents.
3. Could pomegranate fight against SARS-CoV-2?
3.1 Anti-viral action of pomegranate
Pomegranate attenuates many viruses [37]. Polyphenols and ellagic acid were 
proved to neutralized envelope virus via binding to the envelope lipid or sugar  
moieties [38]. Pomegranate juice succeeded to prevent Human immune deficiency 
virus-1 (HIV-1) cell entry by blocking CD4 and coreceptors CXCR4/CCR5  
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binding [39]. Ellagitannins of Pomegranate extract; punicalagin, punicalin and 
ellagic acid blocked the HCV NS3/4A protease activity in an in vitro study [40]. 
Furthermore, the activity of adenovirus was suppressed by Pomegranate peel 
ethanol extract on HeLa cell line. The 50% inhibitory concentration (IC50) and 
50% Cytotoxicity Concentration (CC50) were 165 ± 10.1 and 18.6 ± 6.7 μg/ml, 
respectively [41]. In addition, Pomegranate juice and pomegranate polyphenol 
extract reduced viral titer of noroviruses with other foodborne viral surrogates 
[42]. A viricidal effect of Pomegranate powder extract with 800 μg/ml polyphenols 
was clarified. When the titer of influenza virus (PR8 (H1N1), X31 (H3N2), and a 
reassortant H5N1 virus of human isolate lowered by 3log in 5 min treatment at room 
temperature. This effect was explored by electron microscopy when disruption 
of viral structure appeared [43]. Moreover, the replication and agglutination of 
chicken RBC’s by influenza virus was inhibited by Punicalagin, a phenol in pome-
granate extract. Synergistic effect was noticed in oseltamivir combination [44]. The 
anti Influenza mechanism was emphasized in another study where Pomegranate 
peel ethyl alcohol extract (PPE) inhibited the influenza virus adsorption and repli-
cation though attenuation of viral polymerase activity and protein expression [45].
3.2 Immune modulatory action of pomegranate
Mast cells and basophils have a crucial role in inflammatory and immune 
response [46]. These cells release pro-inflammatory cytokines TNF-α, IL-6, 
IL-8, histamine which initiate acute- and late-phase inflammatory response [47]. 
Cytokine expression is induced by many pathways such as extra-cellular signal-
regulated kinase (ERK), and c-Jun N-terminal kinase (JNK) and Nuclear factor 
(NF)-κB [48–50]. Immune modulation action of pomegranate was confirmed in 
many studies. Pomegranate fruit extract strongly attenuated phorbol-12-myristate 
13-acetate plus calcium inophore A23187 (PMACI) induced inflammatory gene 
expression and reduced the release of interleukin (IL)-6 and IL-8 in the myeloid 
pre-cursor cell line KU812 cells. Through its action on c-jun N-terminal kinase 
(JNK), extracellular-regulated kinase (ERK) and Neucular factor Kappa β (NF-κB) 
dependent pathways [51]. NF-κB signaling stimulation is mediated by IL-1β binding 
to its specific cell surface receptor that activates IKKs with subsequent phosphoryla-
tion and degradation of IκB. This cascade was suppressed in human chondrocyte 
by pomegranate extract. Which interfered with the mRNA and protein expression 
of IL-6 and downregulated the activation of NF-κB/p65. Through inhibition of 
the IL-1β-mediated phosphorylation of IKKβ, expression of IKKβ mRNA and 
degradation of IκBα [52]. Moreover, in another in vitro study, Pomegranate flower 
(PFE) ethanol extract reduced IL-6, IL-1β and TNF-α production with IC50 value of 
48.7, 71.3 and 62.5 μg/mL respectively, in lipo-poly saccharides (LPS) -induced 
RAW264.7 cell macrophage. This effect was attributed to inhibition of phosphoryla-
tion of mitogen-activated protein kinase (MAPK) subgroups, extracellular signal-
regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and P38 and translocation 
of the NF-B p65 subunit [53]. Pomegranate peel extract decreased the secretion of 
CXCL8 in both Caco-2 cells and colonic explants. Furthermore, it attenuated the 
expression of IL 1A, IL 6 and CXCL8 in lipopoly saccharide, LPS stimulated colonic 
tissues at a concentration of 5 g/ml [54].
3.3 Anti-tyrosine kinase action of pomegranate
Janus kinase (JAK) is a member of the non-receptor tyrosine kinase family. It 
triggers many inflammatory signaling pathways like signal transducer and activa-
tion of transcription (STAT) that induce chemotaxis of inflammatory cells such 
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as mast cells, T cell, B cells, macrophages [55]. Baricitinib is a Janus kinase (JAK) 
inhibitor and is a numb-associated kinase NAK inhibitor which attenuates AP2-
associated protein kinase-1 (AAK1), the protein that promotes viral endocytosis 
[56, 57]. Fortunately, Pomegranate shares Baricitinib its janus kinase inhibitory 
action. The fact that introduces Pomegranate as a possible treating agent of SARS-
CoV-2. This action was highlighted in a study where Pomegranate leaf extract 
antagonized Janus Kinase1 (JAK1) enzyme activity in macrophage raw cells [58]. In 
another study, among ellagitannins containing fruits, pomegranate was the superior 
in JAK2 inhibition [59].
3.4 Anti-converting enzyme (ACE) action of Pomegranate
The renin-angiotensin-aldosterone system, RAAS organizes blood pressure, 
fluid balance and controls the vascular response to inflammation [60]. Imbalance in 
that system induces hypertension, fluid retention, and inflammatory and throm-
botic complications [61]. Juxtaglomerular apparatus of the kidney secretes renin 
which acts on angiotensinogen to form Angiotensin I (A1). Angiotensin-converting 
enzyme (ACE) breaks AI to AII. Angiotensin II is the main controlling agent of 
RAAS through stimulation of type 1 receptor (AT1 receptor) with subsequent vaso-
constriction, water retention and inflammation. While The type 2 receptor, ATR2 
counteract these effects [62]. ACE2 counterbalance ACE actions. It breaks down AI 
into angiotensin 1-9(A1-9), and AII into angiotensin 1-7(A1-7) which has vasodila-
tor and anti-proliferative action [63]. The renin-angiotensin system is claimed to 
induce severe acute lung injury in SARS-CoV-2 infection and ACE2 protects against 
acute lung failure and its deficiency is associated with lung damage [64]. Binding of 
SARS-Cov-2 to ACE2 receptor attenuates ACE2 action with subsequent lung dam-
age [65]. On that basis, soluble ACE2 was supposed to be a possible approach for 
coronavirus infection [66]. It was speculated that, The use of ACE Inhibitors is asso-
ciated with increased concentration of angiotensin I which upregulates ACE2 [67]. 
It is ambiguous, whether this postulate increases the probability of SARS-CoV-2 
infection. Or ACE2 upregulation will be beneficial for counterbalance the ACE2 
virus-induced downregulation with improvement of lung defense [65]. Although 
the role of Angiotensin converting enzyme, ACE inhibitors in SARS-CoV-2 infec-
tion is controversial, Pomegranate has the potential of ACE inhibition and may help 
in this battle. Punica granatum juice extract lowered ACE level and mean arterial 
blood pressure. When it was given in a dose of (PJ- 100 mg/kg and 300 mg/kg: p.o.) 
in angiotensin-II treated rats for 4 weeks [68]. Similar effect was emphasized in 
a parallel study. When Pomegranate peel extract was administered to female rats 
for 30 days. It inhibited coronary angiotensin-converting enzyme (ACE) activity 
and oxidative stress [69]. In a clinical trial, Pomegranate juice reduced serum ACE 
activity and systolic blood pressure in hypertensive patients when it was consumed 
for 2 weeks at a dose of (50 ml, 1.5 mmol of total polyphenols per day) [70].
3.5 Anti-SARS-CoV-2 action of pomegranate
Pomegranate potentials against SARS-CoV-2 infection have been investigated in 
many studies.
3.5.1 Anti-SARS-CoV-2 action of pomegranate
In a Computational study, Pomegranate peel extracts components; ellagic acid, 
gallic acid and specially punicalagin, punicalin showed promising anti SARS-CoV-2 
activity through interaction with SARS-CoV-2 spike glycoprotein, angiotensin 
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converting enzyme 2, furin and transmembrane serine protease2. They formed 
more stable complexes with amino acid residues at the active sites of the selected 
protein targets in comparison to positive controls (umifenovir, lopinavir, camostat) 
with more significant binding affinity. Punicalin showed the most potent interac-
tion with the S glycoprotein with free binding energy of −7.406 kcal/mol. All 
Pomegranate components ligands exerted a significant binding affinity at the ACE2 
predicted active site. Furthermore, they formed the most stable complexes with 
furin. Amazingly, Punicalagin and punicalin strongly interacted with TMPRSS2 
amino acid residues at the predicted active site by binding energy values of −7.358 
and − 8.168 kcal/mol, respectively with higher affinity for the target protein than 
camostat (−7.069 kcal/mol). [71]. In an in vitro study, Pomegranate juice reduced 
the infectivity of SARS-Cov-2 and influenza virus in VeroE6 cells [72]. In another 
study, Pomegranate peel extract showed an ability to block the binding between 
SARS-CoV-2 Spike glycoprotein and the human Angiotensin-Converting Enzyme 
2 (ACE2) receptor, furthermore, it downregulated the activity of the virus bind 
3-chymotrypsin-like cysteine protease (3CLPro) (an enzyme which is important for 
viral replication) [73].
3.5.2  Anti-SARS-CoV-2 action of natural compounds that are found in 
pomegranate
In a virtual study, pedunculagin, tercatain, and castalin (hydrolysable tannins) 
showed an ability to bind (3CLPro) catalytic site that is involved in SARS-CoV-2 
replication. Which sheds the light on tannins as possible anti SARS-CoV-2 agents 
[74]. Other virtual study investigated the action of natural compounds on SARS-
CoV-2 Spike protein, viral Protease and RNA-dependent RNA polymerase and host 
cell protease TMPRSS2. Triterpenoids was found to be the superior in blocking the 
Spike protein binding site of SARS-CoV-2 [75].
4. Conclusion
Pomegranate is still surprising the world by its great therapeutic benefits. This 
chapter highlights the anti-SARS-CoV-2 potentials of Pomegranate. Where Anti-
viral, immune modulation, tyrosine kinase and ACE inhibition actions, all enable 
Pomegranate to fight in this war. Further future studies are needed to confirm the 
utility of Pomegranate in treating SARS-CoV-2 infection.
Conflict of interest





Tropical Medicine, Tanta University, Egypt
*Address all correspondence to: elnawasany_s@hotmail.com
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
7
Could Pomegranate Fight Against SARS-CoV-2?
DOI: http://dx.doi.org/10.5772/intechopen.96423
References
[1] Ismail T, Akhtar S, Riaz M. 
Pomegranate Peel and Fruit Extracts: A 
Novel Approach to Avert Degenerative 
Disorders–Pomegranate and 
Degenerative Diseases. InExploring 
the Nutrition and Health Benefits of 
Functional Foods 2017 (pp. 165-184). 
IGI Global.
[2] Goertz A, Ahmad KA. Biological 
activity of phytochemical compounds in 
pomegranate-a review. EC Nutri-tion. 
2015;1:115-127.
[3] Elnawasany S. Clinical Applications 
of Pomegranate. In: Soneji J, 
Nageswara-Rao M, editors.  Breeding 
and Health Benefits of Fruit and Nut 
Crops, Intechopen; 2018. p. 127-148. 
DOI: 10.5772/intechopen. 75962
[4] Cui J, Li F, Shi ZL. Origin and 
evolution of pathogenic coronaviruses. 
Nature Reviews Microbiology. 2019 
Mar;17(3):181-192.
[5] Wu JT, Leung K, Leung GM. 
Nowcasting and forecasting the 
potential domestic and international 
spread of the 2019-nCoV outbreak 
originating in Wuhan, China: a 
modelling study. The Lancet. 2020 Feb 
29;395(10225):689-697.
[6] Hui DS, Azhar EI, Madani TA, 
Ntoumi F, Kock R, Dar O, Ippolito G, 
Mchugh TD, Memish ZA, Drosten C, 
Zumla A. The continuing 2019-nCoV 
epidemic threat of novel coronaviruses 
to global health—The latest 2019 novel 
coronavirus outbreak in Wuhan, China. 
International Journal of Infectious 
Diseases. 2020 Feb 1;91:264-266.
[7] Jiang S, Hillyer C, Du L. Neutralizing 
antibodies against SARS-CoV-2 and 
other human coronaviruses. Trends in 
immunology. 2020 Apr 2
[8] Rabi FA, Al Zoubi MS,  
Kasasbeh GA, Salameh DM, 
Al-Nasser AD. SARS-CoV-2 and 
coronavirus disease 2019: what we know 
so far. Pathogens. 2020 Mar;9(3):231.
[9] Boström KI, Yao Y. Options for 
COVID-19 Entry into Pulmonary 
Cells. Biomedical journal of 
scientific & technical research. 2020 
Aug;29(2):22337.
[10] Hoffmann M, Hofmann-Winkler H, 
Pöhlmann S. Priming time: How 
cellular proteases arm coronavirus 
spike proteins. InActivation of Viruses 
by Host Proteases 2018 (pp. 71-98). 
Springer, Cham.a
[11] Shang J, Ye G, Shi K, Wan Y, Luo C, 
Aihara H, Geng Q, Auerbach A, Li F. 
Structural basis of receptor recognition 
by SARS-CoV-2. Nature. 2020 
May;581(7807):221-224.
[12] Tufan A, GÜLER AA, 
Matucci-Cerinic M. COVID-19, immune 
system response, hyperinflammation 
and repurposing antirheumatic drugs. 
Turkish Journal of Medical Sciences. 
2020 Apr 21;50(SI-1):620-632.
[13] Wang X, Cao R, Zhang H, Liu J, 
Xu M, Hu H, Li Y, Zhao L, Li W, Sun X, 
Yang X. The anti-influenza virus drug, 
arbidol is an efficient inhibitor of SARS-
CoV-2 in vitro. Cell Discovery. 2020 
May 2;6(1):1-5.
[14] Zhu Z, Lu Z, Xu T, Chen C, Yang G, 
Zha T, Lu J, Xue Y. Arbidol monotherapy 
is superior to lopinavir/ritonavir in 
treating COVID-19. Journal of Infection. 
2020 Jul 1;81(1):e21-e23.
[15] Wang M, Cao R, Zhang L, Yang X, 
Liu J, Xu M, Shi Z, Hu Z, Zhong W, 
Xiao G. Remdesivir and chloroquine 
effectively inhibit the recently emerged 
novel coronavirus (2019-nCoV) in vitro. 
Cell research. 2020 Mar;30(3):269-271.
[16] Yao X, Ye F, Zhang M, Cui C,  
Huang B, Niu P, Liu X, Zhao L,  
Pomegranate
8
Dong E, Song C, Zhan S. In vitro 
antiviral activity and projection 
of optimized dosing design of 
hydroxychloroquine for the treatment 
of severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2). Clinical 
Infectious Diseases. 2020 Mar 9.
[17] Monteil V, Kwon H, Prado P, 
Hagelkrüys A, Wimmer RA, Stahl M, 
Leopoldi A, Garreta E, Del Pozo CH, 
Prosper F, Romero JP. Inhibition of 
SARS-CoV-2 infections in engineered 
human tissues using clinical-grade 
soluble human ACE2. Cell. 2020 Apr 24.
[18] Tian X, Li C, Huang A, Xia S, Lu S, 
Shi Z, Lu L, Jiang S, Yang Z, Wu Y, 
Ying T. Potent binding of 2019 novel 
coronavirus spike protein by a SARS 
coronavirus-specific human monoclonal 
antibody. Emerging microbes & 
infections. 2020 Jan 1;9(1):382-385.
[19] Agrawal U, Raju R, Udwadia ZF. 
Favipiravir: A new and emerging 
antiviral option in COVID-19. 
Medical Journal Armed Forces India. 
2020 Sep 2.
[20] Zeng YM, Xu XL, He XQ, Tang SQ, 
Li Y, Huang YQ, Harypursat V, Chen YK. 
Comparative effectiveness and safety 
of ribavirin plus interferon-alpha, 
lopinavir/ritonavir plus interferon-
alpha, and ribavirin plus lopinavir/
ritonavir plus interferon-alpha in 
patients with mild to moderate novel 
coronavirus disease 2019: study 
protocol. Chinese medical journal. 2020 
May 5;133(9):1132-1134.
[21] Mehta P, McAuley DF, Brown M, 
Sanchez E, Tattersall RS, Manson JJ, 
HLH Across Speciality Collaboration. 
COVID-19: consider cytokine storm 
syndromes and immunosuppression. 
Lancet (London, England). 2020 Mar 
28;395(10229):1033.
[22] Ahmed MH, Hassan A. 
Dexamethasone for the Treatment of 
Coronavirus Disease (COVID-19): a 
Review. SN comprehensive clinical 
medicine. 2020 Oct 31:1-0.
[23] Shen C, Wang Z, Zhao F, Yang Y, 
Li J, Yuan J, Wang F, Li D, Yang M, 
Xing L, Wei J. Treatment of 5 critically 
ill patients with COVID-19 with 
convalescent plasma. Jama. 2020 Apr 
28;323(16):1582-1589.
[24] Li L, Zhang W, Hu Y, Tong X, 
Zheng S, Yang J, Kong Y, Ren L, Wei Q, 
Mei H, Hu C. Effect of Convalescent 
Plasma Therapy on Time to Clinical 
Improvement in Patients With Severe 
and Life-threatening COVID-19: A 
Randomized Clinical Trial. Jama. 
2020 Jun 3.
[25] Wang C, Li W, Drabek D, Okba NM, 
van Haperen R, Osterhaus AD, van 
Kuppeveld FJ, Haagmans BL, 
Grosveld F, Bosch BJ. A human 
monoclonal antibody blocking 
SARS-CoV-2 infection. Nature 
communications. 2020 May 4;11(1):1-6.
[26] Brouwer P, Caniels T,  
van Straten K, Snitselaar J, Aldon Y,  
Bangaru S, Torres J, Okba N, 
Claireaux M, Kerster G, Bentlage A. 
Potent neutralizing antibodies from 
COVID-19 patients define multiple 
targets of vulnerability. bioRxiv. 
2020 Jan 1.
[27] Xu X, Han M, Li T, Sun W, Wang D, 
Fu B, Zhou Y, Zheng X, Yang Y, Li X, 
Zhang X. Effective treatment of severe 
COVID-19 patients with tocilizumab. 
Proceedings of the National 
Academy of Sciences. 2020 May 
19;117(20):10970-10975.
[28] Alzghari SK, Acuña VS. Supportive 
treatment with tocilizumab for COVID-
19: a systematic review. Journal of 
Clinical Virology. 2020 Jun;127:104380.
[29] Diurno F, Numis FG, Porta G, 
Cirillo F, Maddaluno S, Ragozzino A, 
De Negri P, Di Gennaro C, Pagano A, 
Allegorico E, Bressy L. Eculizumab 
9
Could Pomegranate Fight Against SARS-CoV-2?
DOI: http://dx.doi.org/10.5772/intechopen.96423
treatment in patients with COVID-
19: preliminary results from real 
life ASL Napoli 2 Nord experience. 
European Review for Medical and 
Pharmacological Sciences. 2020 Apr 
1;24(7):4040-4047.
[30] Stockman LJ, Bellamy R, 
Garner P. SARS: systematic review of 
treatment effects. PLoS Med. 2006 Sep 
12;3(9):e343.
[31] Mantlo E, Bukreyeva N, 
Maruyama J, Paessler S, Huang C. 
Antiviral activities of type I interferons 
to SARS-CoV-2 infection. Antiviral 
research. 2020 Apr 29:104811.
[32] Weisberg E, Parent A, Yang PL,  
Sattler M, Liu Q, Liu Q, Wang J, 
Meng C, Buhrlage SJ, Gray N, Griffin JD. 
Repurposing of kinase inhibitors for 
treatment of COVID-19. Pharmaceutical 
research. 2020 Sep;37(9):1-29.
[33] Jorgensen SC, Tse CL, Burry L, 
Dresser LD. Baricitinib: a review of 
pharmacology, safety, and emerging 
clinical experience in COVID-19. 
Pharmacotherapy: The Journal of 
Human Pharmacology and Drug 
Therapy. 2020 Aug;40(8):843-856.
[34] Rodriguez-Garcia JL, 
Sanchez-Nievas G, Arevalo-Serrano J, 
Garcia-Gomez C, Jimenez-Vizuete JM, 
Martinez-Alfaro E. Baricitinib improves 
respiratory function in patients 
treated with corticosteroids for SARS-
CoV-2 pneumonia: an observational 
cohort study. Rheumatology. 2021 
Jan;60(1):399-407.
[35] Mulgaonkar NS, Wang H, 
Mallawarachchi S, Ruzek D, Martina B, 
Fernando S. Bcr-Abl tyrosine kinase 
inhibitor imatinib as a potential drug for 
COVID-19. bioRxiv. 2020 Jan 1.
[36] Janković S. Current status and 
future perspective of coronavirus 
disease 2019: a review. Scripta Medica. 
2020;51(2):101-109.
[37] Howell AB, D'Souza DH. The 
pomegranate: effects on bacteria and 
viruses that influence human health. 
Evidence-Based Complementary and 
Alternative Medicine. 2013 Oct;2013.
[38] Kotwal GJ. Genetic diversity-
independent neutralization of pandemic 
viruses (eg HIV), potentially pandemic 
(eg H5N1 strain of influenza) and 
carcinogenic (eg HBV and HCV) viruses 
and possible agents of bioterrorism 
(variola) by enveloped virus 
neutralizing compounds (EVNCs). 
Vaccine. 2008;26(24):3055-3058
[39] Neurath AR, STRICK N, LI YY, 
DEBNATH AK. Punica granatum 
(pomegranate) juice provides an 
HIV-1 entry inhibitor and candidate 
topical microbicide. Annals of the 
New York Academy of Sciences. 2005 
Nov;1056(1):311-27.
[40] Reddy BU, Mullick R, Kumar A, 
Sudha G, Srinivasan N, Das S. Small 
molecule inhibitors of HCV replication 
from pomegranate. Scientific reports. 
2014 Jun 24;4:5411.
[41] Karimi A, Moradi MT, Rabiei M, 
Alidadi S. In vitro anti-adenoviral 
activities of ethanol extract, 
fractions, and main phenolic 
compounds of pomegranate (Punica 
granatum L.) peel. Antiviral 
Chemistry and Chemotherapy. 2020 
Apr;28:2040206620916571.
[42] Su X, Sangster MY, D'Souza DH. 
In vitro effects of pomegranate juice 
and pomegranate polyphenols on 
foodborne viral surrogates. Foodborne 
Pathogens and Disease. 2010 Dec 
1;7(12):1473-1479.
[43] Sundararajan A, Ganapathy R,  
Huan L, Dunlap JR, Webby RJ, 
Kotwal GJ, Sangster MY. Influenza virus 
variation in susceptibility to inactivation 
by pomegranate polyphenols is 
determined by envelope glycoproteins. 
Antiviral research. 2010 Oct 1;88(1):1-9.
Pomegranate
10
[44] Haidari M, Ali M, Casscells III 
SW, Madjid M. Pomegranate (Punica 
granatum) purified polyphenol 
extract inhibits influenza virus 
and has a synergistic effect with 
oseltamivir. Phytomedicine. 2009 Dec 
1;16(12):1127-1136.
[45] Moradi MT, Karimi A, Rafieian-
kopaei M, Rabiei-Faradonbeh M, 
Momtaz H. Pomegranate peel extract 
inhibits internalization and replication 
of the influenza virus: An in vitro study. 
Avicenna Journal of Phytomedicine. 
2020 Mar;10(2):143.
[46] Galli SJ. New concepts about the 
mast cell. New England Journal of 
Medicine. 1993 Jan 28;328(4):257-265.
[47] Woolley DE, Tetlow LC. Mast 
cell activation and its relation to 
proinflammatory cytokine production 
in the rheumatoid lesion. Arthritis 
Research & Therapy. 1999 Dec;2(1):1-0.
[48] Cobb MH, Goldsmith EJ. 
Dimerization in MAP-kinase signaling. 
Trends in biochemical sciences. 2000 
Jan 1;25(1):7-9.
[49] Lewis TS, Shapiro PS, Ahn NG. 
Signal transduction through MAP 
kinase cascades. In Advances in cancer 
research 1998 Jan 1 (Vol. 74, pp. 49-139). 
Academic Press.
[50] Collart MA, Baeuerle P, Vassalli P. 
Regulation of tumor necrosis factor 
alpha transcription in macrophages: 
involvement of four kappa B-like motifs 
and of constitutive and inducible forms 
of NF-kappa B. Molecular and cellular 
biology. 1990 Apr 1;10(4):1498-1506.
[51] Rasheed Z, Akhtar N, 
Anbazhagan AN, Ramamurthy S, 
Shukla M, Haqqi TM. Polyphenol-rich 
pomegranate fruit extract (POMx) 
suppresses PMACI-induced expression 
of pro-inflammatory cytokines by 
inhibiting the activation of MAP 
Kinases and NF-κB in human KU812 
cells. Journal of inflammation. 2009  
Dec 1;6(1):1.
[52] Haseeb A, Khan NM, Ashruf OS,  
Haqqi TM. A polyphenol-rich 
pomegranate fruit extract suppresses 
NF-κB and IL-6 expression by 
blocking the activation of IKKβ and 
NIK in primary human chondrocytes. 
Phytotherapy Research. 2017 
May;31(5):778-782.
[53] Xu J, Zhao Y, Aisa HA. Anti-
inflammatory effect of pomegranate 
flower in lipopolysaccharide (LPS)-
stimulated RAW264. 7 macrophages. 
Pharmaceutical Biology. 2017 Jan 
1;55(1):2095-2101.
[54] Mastrogiovanni F, Mukhopadhya A,  
Lacetera N, Ryan MT, Romani A,  
Bernini R, Sweeney T. Anti-
inflammatory effects of pomegranate 
peel extracts on in vitro human 
intestinal caco-2 cells and ex vivo 
porcine colonic tissue explants. 
Nutrients. 2019 Mar;11(3):548.
[55] Wong WF, Leong KP. Tyrosine 
kinase inhibitors: a new approach for 
asthma. Biochimica et Biophysica Acta 
(BBA)-Proteins and Proteomics. 2004 
Mar 11;1697(1-2):53-69.
[56] Stebbing J, Phelan A, 
Griffin I, Tucker C, Oechsle O, Smith D, 
Richardson P. COVID-19: combining 
antiviral and anti-inflammatory 
treatments. The Lancet Infectious 
Diseases. 2020 Apr 1;20(4):400-402.
[57] Richardson P, Griffin I,  
Tucker C, Smith D, Oechsle O, 
Phelan A, Stebbing J. Baricitinib as 
potential treatment for 2019-nCoV 
acute respiratory disease. Lancet 
(London, England). 2020 Feb 
15;395(10223):e30.
[58] Sarithamol S, Pushpa VL, 
Manoj KB. Comparative Study on Janus 
Kinase Enzyme activity of Pomegranate 
Leaf Extract and its Active Component 
11
Could Pomegranate Fight Against SARS-CoV-2?
DOI: http://dx.doi.org/10.5772/intechopen.96423
Ellagic Acid for Asthma. Oriental 
Journal of Chemistry. 2018;34(2):1041.
[59] Martin H, Burgess EJ, Smith WA, 
McGhie TK, Cooney JM, Lunken RC, de 
Guzman E, Trower T, Perry NB. JAK2 
and AMP-kinase inhibition in vitro by 
food extracts, fractions and purified 
phytochemicals. Food & function. 
2015;6(1):304-311.
[60] Ferrario CM. Role of angiotensin II 
in cardiovascular disease—therapeutic 
implications of more than a century 
of research. Journal of the Renin-
angiotensin-aldosterone System. 2006 
Mar;7(1):3-14.
[61] Brewster UC, Perazella MA. The 
renin-angiotensin-aldosterone system 
and the kidney: effects on kidney 
disease. The American journal of 
medicine. 2004 Feb 15;116(4):263-272.
[62] Zaman MA, Oparil S, Calhoun DA. 
Drugs targeting the renin–angiotensin–
aldosterone system. Nature reviews 
Drug discovery. 2002 Aug;1(8):621-636.
[63] Macia-Heras M, Del 
Castillo-Rodriguez N, Navarro 
González J. The renin-angiotensin-
aldosterone system in renal and 
cardiovascular disease and the effects of 
its pharmacological blockade. J Diabetes 
Metab. 2012 Feb 1;3(2).
[64] Kuba K, Imai Y, Rao S, 
Gao H, Guo F, Guan B, Huan Y, Yang P, 
Zhang Y, Deng W, Bao L. A crucial role 
of angiotensin converting enzyme 2 
(ACE2) in SARS coronavirus–induced 
lung injury. Nature medicine. 2005 
Aug;11(8):875-879.
[65] Perrotta F, Matera MG, Cazzola M, 
Bianco A. Severe respiratory SARS-
CoV2 infection: Does ACE2 receptor 
matter?. Respiratory Medicine. 2020 
Apr 25:105996.
[66] Batlle D, Wysocki J, Satchell K. 
Soluble angiotensin-converting  
enzyme 2: a potential approach for 
coronavirus infection therapy?. 
Clinical science. 2020 Mar 
13;134(5):543-545.
[67] Tikellis C, Thomas MC. 
Angiotensin-converting enzyme 2 
(ACE2) is a key modulator of the 
renin angiotensin system in health 
and disease. International journal of 
peptides. 2012;2012.
[68] Harshal W, Mahalaxmi M, 
Sanjay K, Balaraman R. Punica granatum 
attenuates angiotensin-II induced 
hypertension in Wistar rats. 
International Journal of PharmTech 
Research. 2010;2(1):60-67.
[69] dos Santos RL, Dellacqua LO, 
Delgado NT, Rouver WN, Podratz PL, 
Lima LC, Piccin MP, Meyrelles SS, 
Mauad H, Graceli JB, Moyses MR. 
Pomegranate peel extract attenuates 
oxidative stress by decreasing coronary 
angiotensin-converting enzyme 
(ACE) activity in hypertensive 
female rats. Journal of Toxicology and 
Environmental Health, Part A. 2016 
Nov 1;79(21):998-1007.
[70] Aviram M, Dornfeld L. 
Pomegranate juice consumption inhibits 
serum angiotensin converting enzyme 
activity and reduces systolic blood 
pressure. Atherosclerosis. 2001 Sep 
1;158(1):195-198.
[71] Suručić R, Tubić B, Stojiljković MP, 
Djuric DM, Travar M, Grabež M, 
Šavikin K, Škrbić R. Computational 
study of pomegranate peel extract 
polyphenols as potential inhibitors 
of SARS-CoV-2 virus internalization. 
Molecular and cellular biochemistry. 
2020 Nov 16:1-5.
[72] Conzelmann C, Weil T, Groß R, 
Jungke P, Frank B, Eggers M, Müller JA, 
Münch J. Antiviral activity of plant 
juices and green tea against SARS-CoV-2 




[73] Tito A, Colantuono A, Pirone L,  
Pedone EM, Intartaglia D, Giamundo G,  
Conte I, Vitaglione P, Apone F. A 
pomegranate peel extract as inhibitor 
of SARS-CoV-2 Spike binding to human 
ACE2 (in vitro): a promising source 
of novel antiviral drugs. bioRxiv. 
2020 Jan 1.
[74] Khalifa I, Zhu W, Mohammed HH, 
Dutta K, Li C. Tannins inhibit SARS-
CoV-2 through binding with catalytic 
dyad residues of 3CLpro: An in silico 
approach with 19 structural different 
hydrolysable tannins. Journal of food 
biochemistry. 2020 Oct;44(10):e13432.
[75] Gowtham HG, Monu DO, Ajay Y, 
Gourav C, Vasantharaja R, Bhani K, 
Koushalya S, Shazia S, Priyanka G, 
Leena C. Exploring structurally 
diverse plant secondary metabolites 
as a potential source of drug targeting 
different molecular mechanisms of 
Severe Acute Respiratory Syndrome 
Coronavirus-2 (SARS-CoV-2) 
pathogenesis: An in silico approach.
